modulation (Muriel 2007). IFN-α is considered as a hallmark in treating viral
hepatitis, the major cause of liver cirrhosis and hepatocellular cancer all over the
world. IFNs are also known to cause the production of matrix proteins such as
fibronectin and collagen. Muriel et al., demonstrated the effect of IFN-α2b on fibrosis
and cirrhosis induced by CCl4 in rats. Furthermore, there is a recovery of hepatocyte
and erythrocyte membranes to its normal composition as a result of antifibrotic
effects on IFNs (Muriel et al. 1994a; Muriel 1995). A study also demonstrated that
there is downregulation of collagen gene transcription and suppression of CCl4
hepatic fibrosis in mice by IFN-α. Mukai et al., in 2006 showed that IFN-γ prevents
liver fibrosis in nonobese diabetic mice. IFN-α2a causes the reversal of hepatic
cirrhosis induced by thioacetamide in rats (Mathew et al. 2007).
29.2.3 Nitric Oxide
Nitric oxide (NO) gas was investigated as an endogenous vasodilator (Palmer et al.
1987). It is produced from L-arginine by NO synthases, and its synthesis is regulated
by the liver (Muriel 2000). NO helps in regulating the proper functioning of every
organ in the body, and its alteration is involved in various hepatic disorders. NO is
beneficial to maintain the integrity of microvascular function and inhibits the platelet
aggregation and neutrophil infiltration to prevent apoptosis. It also acts as second
messenger in harmful and helpful cytokine signalling. Hence, the modulation of NO
synthesis and NO donors, especially which are liver-specific, can be a powerful tool
in the treatment of liver disorders in future (Muriel 2006).
29.2.4 Sulfoadenosylmethionine (SAM)
SAM is an endogenous molecule which participates in liver health and diseases
(Mato and Lu 2007). The three distinct enzymes that synthesize SAM in mammals
are methionine adenosyltransferase (MAT) I, II and III. The synthesis and utilization
of SAM occur mainly in the liver via MATI, MATIII and glycine N-
methyltransferase, and these three enzymes are responsible for the synthesis and
removal of hepatic SAM (Mato et al. 2002). It has been previously demonstrated that
there is an alteration of methionine metabolism in patients with liver disease. A study
conducted by Kinsell et al. (1948) showed that there is a significant impairment in
the methionine clearance after methionine load in patients having liver disease, and
this suggests the important role of liver in the metabolism of methionine. In most of
transmethylation
reactions,
SAM
is
a
methyl
donor
and
is
utilized
by
methyltransferases in synthesizing various biological compounds including plasma
membrane lipids (Muriel and Mourelle 1992; Muriel 1993). MAT and SAM are
significantly reduced in case of experimental and human hepatic damage (Mato and
Lu 2007). Treatment of animals with SAM showed prevention in the prolonged
biliary obstruction-induced cirrhosis (Muriel et al. 1994b). In another study, the
administration of SAM to alcohol-fed mice, rats and baboons attenuated the
560
H. Singh et al.